Health Catalyst (NASDAQ:HCAT) Releases Earnings Results, Misses Expectations By $0.24 EPS

Health Catalyst (NASDAQ:HCAT - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.24), Zacks reports. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The business had revenue of $79.61 million for the quarter, compared to analyst estimates of $79.59 million. Health Catalyst updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

Health Catalyst Stock Up 6.4 %

Health Catalyst stock traded up $0.28 during midday trading on Friday, hitting $4.67. 2,010,813 shares of the stock were exchanged, compared to its average volume of 844,833. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The company has a 50 day moving average price of $5.98 and a two-hundred day moving average price of $7.24. The firm has a market cap of $284.16 million, a P/E ratio of -3.46 and a beta of 1.34. Health Catalyst has a 1 year low of $3.76 and a 1 year high of $9.24.

Analyst Upgrades and Downgrades

HCAT has been the topic of a number of research analyst reports. Citigroup reduced their target price on Health Catalyst from $10.50 to $10.00 and set a "buy" rating on the stock in a report on Friday, January 10th. Piper Sandler reduced their price objective on Health Catalyst from $12.00 to $8.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 11th. Royal Bank of Canada dropped their target price on shares of Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating for the company in a research report on Thursday. Stifel Nicolaus reduced their price target on shares of Health Catalyst from $10.00 to $5.00 and set a "hold" rating on the stock in a research report on Thursday. Finally, KeyCorp raised shares of Health Catalyst from a "sector weight" rating to an "overweight" rating and set a $9.00 price objective for the company in a research report on Wednesday, January 8th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $9.45.

Remove Ads

Insider Activity

In other news, Director Duncan Gallagher sold 4,500 shares of Health Catalyst stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $6.98, for a total value of $31,410.00. Following the completion of the transaction, the director now directly owns 74,438 shares of the company's stock, valued at approximately $519,577.24. The trade was a 5.70 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of the company's stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $8.94, for a total value of $67,050.00. Following the transaction, the insider now owns 236,950 shares of the company's stock, valued at approximately $2,118,333. The trade was a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 87,610 shares of company stock worth $664,043 over the last ninety days. Corporate insiders own 2.50% of the company's stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.